x

Hledat klinickou studii

* (*) povinné pole

4 Výsledků

Studie přijímající pacienty = Studie přijímající pacienty
; Probíhající studie = Probíhající studie; Ukončená studie = Ukončená studie; Financováno členem konsorcia IRDiRC = ; Člen ERN =

Národní klinické studie

SPOJENÉ KRÁLOVSTVÍ

Tyne & Wear
NEWCASTLE UPON TYNE

MISSING CONTENTAn open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK -
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

SPOJENÉ KRÁLOVSTVÍ

Tyne & Wear
NEWCASTLE UPON TYNE

MISSING CONTENTAn open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK -
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

SPOJENÉ KRÁLOVSTVÍ

Tyne & Wear
NEWCASTLE UPON TYNE

MISSING CONTENTAn open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

SPOJENÉ KRÁLOVSTVÍ

Tyne & Wear
NEWCASTLE UPON TYNE

MISSING CONTENTAn open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine